ArticleJournal of inflammation (London, England)2011
Always one step ahead: How pathogenic bacteria use the type III secretion system to manipulate the intestinal mucosal immune system.
Article in Journal of inflammation (London, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Genome on the move: emergence of hybrid atypical enteropathogenic/enteroaggregativeMicrobiology spectrum · 2026Article
- A post-invasion role forThe Journal of biological chemistry · 2020Article
- Genetic and Virulence Characteristics of a Hybrid Atypical Enteropathogenic and UropathogenicFrontiers in cellular and infection microbiology · 2020Article
- Virulence gene profiles and molecular genetic characteristics of diarrheagenicGut pathogens · 2018Article
- Diarrheagenic Escherichia coli.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2016Review
- Tight Junction Disruption Induced by Type 3 Secretion System Effectors Injected by Enteropathogenic and Enterohemorrhagic Escherichia coli.Frontiers in cellular and infection microbiology · 2016Review
- Type III Secretion-Dependent Sensitivity of Escherichia coli O157 to Specific Ketolides.Antimicrobial agents and chemotherapy · 2016Article
- Distribution of non-LEE-encoded type 3 secretion system dependent effectors in enteropathogenic Escherichia coli.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2014Article
- Effect of HIV and chlamydia infection on rectal inflammation and cytokine concentrations in men who have sex with men.Clinical and vaccine immunology : CVI · 2013Article
- Gut homeostasis in a microbial world: insights from Drosophila melanogaster.Nature reviews. Microbiology · 2013Review
- The enteropathogenic Escherichia coli-secreted protein EspZ inhibits host cell apoptosis.Infection and immunity · 2012Article
- Inflammation and disintegration of intestinal villi in an experimental model for Vibrio parahaemolyticus-induced diarrhea.PLoS pathogens · 2012Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The intestinal immune system and the epithelium are the first line of defense in the gut. Constantly exposed to microorganisms from the environment, the gut has complex defense mechanisms to prevent infections, as well as regulatory pathways to tolerate commensal bacteria and food antigens. Intestinal pathogens have developed strategies to regulate intestinal immunity and inflammation in order to establish or prolong infection. The organisms that employ a type III secretion system use a molecular syringe to deliver effector proteins into the cytoplasm of host cells. These effectors target the host cell cytoskeleton, cell organelles and signaling pathways. This review addresses the multiple mechanisms by which the type III secretion system targets the intestinal immune response, with a special focus on pathogenic E. coli.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.